In last trading session, Sangamo Therapeutics Inc (NASDAQ:SGMO) saw 5.87 million shares changing hands with its beta currently measuring 1.21. Company’s recent per share price level of $0.44 trading at -$0.02 or -4.78% at ring of the bell on the day assigns it a market valuation of $102.13M. That closing price of SGMO’s stock is at a discount of -622.73% from its 52-week high price of $3.18 and is indicating a premium of 31.82% from its 52-week low price of $0.30. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 5.98 million shares which gives us an average trading volume of 6.99 million if we extend that period to 3-months.
For Sangamo Therapeutics Inc (SGMO), analysts’ consensus is at an average recommendation of Hold while assigning it a mean rating of 1.71. Splitting up the data highlights that, out of 3 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 2 suggested the stock as a Hold whereas 1 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.1 in the current quarter.
Sangamo Therapeutics Inc (NASDAQ:SGMO) trade information
Upright in the red during last session for losing -4.78%, in the last five days SGMO remained trading in the red while hitting it’s week-highest on Monday, 05/12/25 when the stock touched $0.44 price level, adding 42.29% to its value on the day. Sangamo Therapeutics Inc’s shares saw a change of -57.06% in year-to-date performance and have moved -32.66% in past 5-day. Sangamo Therapeutics Inc (NASDAQ:SGMO) showed a performance of -41.64% in past 30-days. Number of shares sold short was 28.25 million shares which calculate 2.71 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 2.5 to the stock, which implies a rise of 82.4% to its current value. Analysts have been projecting 2 as a low price target for the stock while placing it at a high target of 3. It follows that stock’s current price would drop -354.55% in reaching the projected high whereas dropping to the targeted low would mean a loss of -354.55% for stock’s current value.
Sangamo Therapeutics Inc (SGMO) estimates and forecasts
This year revenue growth is estimated to fall -32.30% from the last financial year’s standing.
5 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 15.88M for the same. And 5 analysts are in estimates of company making revenue of 7M in the next quarter. Company posted 356k and 49.41M of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 10.57% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 25.07% while estimates for its earnings growth in next 5 years are of 20.66%.
Sangamo Therapeutics Inc (NASDAQ:SGMO)’s Major holders
Insiders are in possession of 2.91% of company’s total shares while institution are holding 28.48 percent of that, with stock having share float percentage of 29.33%. Investors also watch the number of corporate investors in a company very closely, which is 28.48% institutions for Sangamo Therapeutics Inc that are currently holding shares of the company. WASATCH ADVISORS LP is the top institutional holder at SGMO for having 20.09 million shares of worth $7.2 million. And as of 2024-06-30, it was holding 9.8509 of the company’s outstanding shares.
The second largest institutional holder is ARMISTICE CAPITAL, LLC, which was holding about 14.06 million shares on 2024-06-30. The number of shares represents firm’s hold over 6.894 of outstanding shares, having a total worth of $5.04 million.
On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and WASATCH FUNDS TRUST-Wasatch Ultra Growth Fund are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 5.65 shares of worth $2.47 million or 2.46% of the total outstanding shares. The later fund manager was in possession of 4.53 shares on Mar 31, 2025 , making its stake of worth around $1.98 million in the company or a holder of 1.98% of company’s stock.
